Azithromycin for injection

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

Main ingredients: The main ingredient of this product is azithromycin. Its chemical name is (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta;-D-xyl-pyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Structural formula: (see azithromycin dry suspension) Molecular formula: C38H72N2O12 Molecular weight: 749

This product is suitable for the following infections caused by sensitive pathogenic strains. 1. Community-acquired pneumonia caused by Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus or Streptococcus pneumoniae, which requires intravenous drip treatment first. 2. Pelvic inflammatory disease caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma hominis, which requires intravenous drip treatment first.

Dissolve this product in an appropriate amount of water for injection to prepare 0.1g/ml, then add it to 250ml or 500ml of sodium chloride injection or 5% glucose injection. The final azithromycin concentration is 1.0-2.Omg/ml, and then drip it intravenously. The concentration is 1.0mg/ml, and the drip time is 3 hours; the concentration is 2.0mg/ml, and the drip time is 1 hour. 1. Treatment of community-acquired pneumonia: 0.5g for adults once a day, once a day, for at least 2 consecutive days, followed by azithromycin oral preparations 0.5g a day, 7-10 days as a course of treatment. The time to switch to oral treatment should be determined by the physician based on the clinical treatment response. 2. Treatment of pelvic inflammatory disease: g for adults once a day, once a day, after 1 or 2 days of medication, switch to azithromycin oral preparations 0.25g a day, 7 days as a course of treatment. The time to switch to oral treatment should be determined by the physician based on the clinical treatment response.

1. Common adverse reactions of this product include: (1) Gastrointestinal reactions: diarrhea, abdominal pain, loose stools, nausea, vomiting, etc. (2) Local reactions: pain at the injection site, local inflammation, etc. (3) Skin reactions: rash, itching. (4) Other reactions: such as loss of appetite, vaginitis, stomatitis, dizziness or dyspnea, etc. 2. This product may also cause the following reactions: (1) Digestive system: indigestion, flatulence, mucositis, oral candidiasis, gastritis, etc. (2) Nervous system: headache, drowsiness, etc. (3) Allergic reactions: bronchospasm, etc. (4) Other reactions: abnormal taste, etc. (5) Laboratory tests: increased serum aminotransferase, creatinine, lactate dehydrogenase, bilirubin and alkaline phosphatase, decreased white blood cell, neutrophil and platelet counts.

It is contraindicated in patients who are allergic to azithromycin, erythromycin, or any other macrolide drugs.

Precautions for children: The safety of this product for patients under 16 years old is not clear. Precautions for pregnancy and lactation: Animal experiments show that this product has no effect on the fetus, but there is still a lack of experience in its use in pregnant women, so the pros and cons must be fully weighed before using it in pregnant women. There is no data to show whether this product can be secreted into breast milk, so the use of this product in lactating women must be considered with caution. Precautions for the elderly:

1. When used in combination with theophylline, the latter's concentration in plasma can be increased, and attention should be paid to detecting plasma theophylline levels. 2. When used in combination with warfarin, attention should be paid to checking the prothrombin time. 3. When used simultaneously with the following drugs, it is recommended to closely observe the patient. Digoxin increases digoxin levels. Ergotamine or dihydroergotamine causes acute ergot toxicity, with symptoms of severe peripheral vasospasm and dysesthesia (pain when touching objects). Triazolam enhances the pharmacological effects of triazolam by reducing its degradation. Cytochrome P450 system metabolites increase the levels of carbamazepine, terfenadine, cyclosporine, cyclohexylbarbital, and phenytoin in serum. 4. When used in combination with rifabutin, the latter's toxicity will be increased.

Keep away from light, tightly closed and in a dry place.

0.125 g (125,000 units)

Kaifeng Kangnuo Pharmaceutical Co., Ltd.

• Founded in:

  2003-09-26

• Address:

  No. 66, South Section of Jinming Avenue, Nanyuan Street, Gulou District, Kaifeng City, Henan Province

• Tax NO.:

  91410200753894686D

• Registered Funds:

  8.99 million yuan

• Website:

  Log in to view

• Email:

  Log in to view